Özlem KORKMAZ, Damla GÖKŞEN, Samim ÖZEN, ŞÜKRAN DARCAN

Is anti-Mullerian hormone an indicator of potential polycystic ovary syndrome in prepubertal girls with simple obesity?

Korkmaz Ö, Gökşen D, Özen S, Darcan Ş. Is anti-Mullerian hormone an indicator of potential polycystic ovary syndrome in prepubertal girls with simple obesity? Turk J Pediatr 2016; 58: 406-412.The aim of this anti-Mullerian hormone (AMH) levels in prepubertal obese girls are a predictive marker for polycystic ovary syndrome (PCOS) and to investigate the relationship between insulin resistance and AMH. Sixty girls with premature pubarche or obesity and 20 healthy controls between the ages of 6-9 were enrolled. Of the patients, 22 (36.7%) were in the obese group (Group 1), 28 (46.7%) in the early pubarche group (Group 2) and 10 (16.6%) in the early pubarche + obese group (Group 3). Comparison of the subjects' fasting insulin and homeostatic model assessment insulin resistance (HOMA-IR) demonstrated significantly higher values for group 1 compared to group 2 (p=0.001 and 0.001) and, likewise, significantly higher values for group 3 compared to group 2. There was no significant differences between all groups for AMH levels.AMH levels were not significantly different in the obese girls compared to the other groups. There was also no relationship between AMH and insulin resistance in any of the groups. Further studies, however, are needed due the limited number of subjects in this study and in the absence of adequate relevant data.

PDF

___

1. Pellatt L, Rice S, Mason HD. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010; 139: 825-833.

2. Itman C, Mendis S, Barakat B, Loveland KL. All in the family: TGF-beta family action in testis development. Reproduction 2006; 132: 233-246.

3. Norman RJ, Wu R, Stankiewicz MT. Polycystic ovary syndrome. Med J Aust 2004; 180: 132-137.

4. Utriainen P, Jaaskelainen J, Voutilainen R. Serum antimullerian hormone concentrations in prepubertal girls with and without premature adrenarche: The influence of body mass index. Horm Res Paediatr 2010; 74: 207-211.

5. Crisosto N, Codner E, Maliqueo M, et al. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 2739-2743.

6. Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME. Serum Mullerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 2005; 84: 938- 944.

7. La Marca A, Orvieto R, Giulini S, et al. Mullerianinhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004; 82: 970-972.

8. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol (Oxf) 2001; 55: 667-672.

9. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 162-168.

10. Greulich WW, Pyle Sl. Radiographic Atlas of Skeletal Devolepment of the Hand and Wrist. (2nd ed). Stanford: Stanford University Press, 1958: 125-228.

11. Tanner JM. Recording adolescent physical changes: Tanner system. Del Med J 1973; 45: 84-88.

12. Neyzi O, Binyıldız P, Alp H. Türk çocuklarında büyüme ve gelişme normları. I-tartı ve boy değerleri. İstanbul Tıp Fakültesi Mecmuası, 1978; 41 (Suppl.74): 1-22.

13. Kajaia N, Binder H, Dittrich R, et al. Low sex hormonebinding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. Eur J Endocrinol 2007; 157: 499-507.

14. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.

15. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005; 90: 3236-3242.

16. Eldar-Geva T, Margalioth EJ, Gal M, et al. Serum antiMullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005; 20: 1814-1819.

17. Oncul M, Sahmay S, Tuten A, et al. May AMH levels distinguish LOCAH from PCOS among hirsute women? Eur J Obstet Gynecol Reprod Biol 2014; 178: 183-187.

18. Woo HY, Kim KH, Rhee EJ, Park H, Lee MK. Differences of the association of anti-Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J 2012; 59: 781-790.

19. Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 787-796.

20. Park AS, Lawson MA, Chuan SS, et al. Serum anti-mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrinol Metab 2010; 95: 1786-1792.

21. Thomson RL, Buckley JD, Moran LJ, et al. The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009; 24: 1976-1981.

22. Andersen CY, Byskov AG. Estradiol and regulation of anti-Mullerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles' fluid. J Clin Endocrinol Metab 2006; 91: 4064-4069.

23. Ledoux S, Campos DB, Lopes FL, et al. Adiponectin induces periovulatory changes in ovarian follicular cells. Endocrinology 2006; 147: 5178-5186.

24. Woo HY, Kim KH, Rhee EJ, Park H, Lee MK. Differences of the association of anti-Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J 2012; 59: 781-790.